International consensus guidance for management of myasthenia gravis: 2020 update
P Narayanaswami, DB Sanders, G Wolfe, M Benatar… - Neurology, 2021 - AAN Enterprises
Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis
PM Rodríguez Cruz, J Cossins, D Beeson… - Frontiers in molecular …, 2020 - frontiersin.org
The neuromuscular junction (NMJ) is a highly specialized synapse between a motor neuron
nerve terminal and its muscle fiber that are responsible for converting electrical impulses …
nerve terminal and its muscle fiber that are responsible for converting electrical impulses …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
JF Howard, S Bresch, A Genge… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …
disease, often accompanied by high treatment burden and with an unmet need for more …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Regulatory T cells in multiple sclerosis and myasthenia gravis
KM Danikowski, S Jayaraman… - Journal of …, 2017 - Springer
Multiple sclerosis (MS) is a chronic debilitating disease of the central nervous system
primarily mediated by T lymphocytes with specificity to neuronal antigens in genetically …
primarily mediated by T lymphocytes with specificity to neuronal antigens in genetically …
Seronegative autoimmune diseases: A challenging diagnosis
Autoimmune diseases (AID) are increasingly prevalent conditions which comprise more
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders
JJGM Verschuuren, J Palace, H Murai… - The Lancet …, 2022 - thelancet.com
Summary Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-
mediated autoimmune diseases of the neuromuscular junction that usually present with …
mediated autoimmune diseases of the neuromuscular junction that usually present with …
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
C Nelke, F Stascheit, C Eckert, M Pawlitzki… - Journal of …, 2022 - Springer
Background Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG)
are associated with significant lethality and continue to impose a high disease burden on …
are associated with significant lethality and continue to impose a high disease burden on …
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX …
GI Wolfe, HJ Kaminski, IB Aban, G Minisman… - The Lancet …, 2019 - thelancet.com
Summary Background The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis
Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone …
Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone …